What is the current valuation of the Gene Therapy Market as of 2024?

The Gene Therapy Market was valued at 6.12 USD Billion in 2024. Read More

What is the projected market size for the Gene Therapy Market by 2035?

The market is projected to reach 41.63 USD Billion by 2035. Read More

What is the expected CAGR for the Gene Therapy Market during the forecast period 2025 - 2035?

The expected CAGR for the Gene Therapy Market during 2025 - 2035 is 19.04%. Read More

Which companies are considered key players in the Gene Therapy Market?

Key players include Novartis, Gilead Sciences, Spark Therapeutics, and Bluebird Bio, among others. Read More

What are the main segments of the Gene Therapy Market based on vector type?

The main segments based on vector type are Viral Vector, valued at 25.0 USD Billion, and Non-Viral Vector, valued at 16.63 USD Billion. Read More

How do the different gene types perform in the Gene Therapy Market?

In 2024, Antigen and Tumor Suppressor gene types were valued at 5.5 USD Billion and 6.2 USD Billion, respectively. Read More

What applications dominate the Gene Therapy Market?

Oncological Disorders and Rare Diseases are leading applications, valued at 5.92 USD Billion and 8.12 USD Billion in 2024. Read More

What delivery methods are utilized in the Gene Therapy Market?

The market segments include In Vivo Gene Therapy, projected to reach 25.09 USD Billion, and Ex Vivo Gene Therapy, expected to reach 16.54 USD Billion. Read More

What is the potential growth of the Gene Therapy Market in the coming years?

The Gene Therapy Market appears poised for substantial growth, with projections indicating a significant increase by 2035. Read More

How does the Gene Therapy Market compare to other biopharmaceutical sectors?

The Gene Therapy Market, with its projected growth, suggests a robust position compared to other biopharmaceutical sectors, particularly in innovative treatments. Read More

Gene Therapy Market

ID: MRFR/Pharma/6927-CR

167 Pages

Nidhi Mandole

Last Updated: July 21, 2026

Gene Therapy Market Research Report: Size, Share, Trend Analysis By Vector Type (Viral Vector (Lentiviral Vectors (LVVs), Retrovirus Vectors, Adenoviral Vectors (AdVs), Adeno-associated Viral Vectors (AAVs) and Non-Viral Vector (Physical Vector, Chemical Vector), by Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), By Applications (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, and Others), by Delivery Method (In Vivo Gene Therapy and Ex Vivo Gene Therapy) and Region (North America, Europe, Asia-Pacific, Rest of the World)) - Growth Outlook & Industry Forecast 2025 To 2035

Gene Therapy Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)19.04%

2024 Market Size$ 6.12 Billion

2025 Market Size$ 7.28 Billion

2035 Market Size$ 41.63 Billion

Key Players

Companies such as Novartis

Gilead Sciences

Spark Therapeutics

Bluebird Bio

Bristol-Myers Squibb

Sangamo Therapeutics

Trends

Increased Investment in Research and Development
Regulatory Advancements
Focus on Personalized Medicine

Opportunities

Increasing Funding and Investment
Growing Demand for Targeted Therapies
Rising Prevalence of Genetic Disorders

Summary Table of Contents Segmentation Methodology Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Vector Type (USD Billion) | |
  1. 4.1.1 Viral Vector | |
  2. 4.1.2 Non-Viral Vector |
2. 4.2 Healthcare, BY Gene Type (USD Billion) | |
  1. 4.2.1 Antigen | |
  2. 4.2.2 Cytokine | |
  3. 4.2.3 Tumor Suppressor | |
  4. 4.2.4 Suicide | |
  5. 4.2.5 Deficiency | |
  6. 4.2.6 Growth Factors | |
  7. 4.2.7 Receptors | |
  8. 4.2.8 Others |
3. 4.3 Healthcare, BY Application (USD Billion) | |
  1. 4.3.1 Oncological Disorders | |
  2. 4.3.2 Rare Diseases | |
  3. 4.3.3 Cardiovascular Diseases | |
  4. 4.3.4 Neurological Disorders | |
  5. 4.3.5 Infectious Diseases | |
  6. 4.3.6 Others |
4. 4.4 Healthcare, BY Delivery Method (USD Billion) | |
  1. 4.4.1 In Vivo Gene Therapy | |
  2. 4.4.2 Ex Vivo Gene Therapy |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Novartis (CH) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Gilead Sciences (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Spark Therapeutics (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Bluebird Bio (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Bristol-Myers Squibb (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Sangamo Therapeutics (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 CRISPR Therapeutics (CH) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 AstraZeneca (GB) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Roche (CH) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY VECTOR TYPE |
7. 6.4 US MARKET ANALYSIS BY GENE TYPE |
8. 6.5 US MARKET ANALYSIS BY APPLICATION |
9. 6.6 US MARKET ANALYSIS BY DELIVERY METHOD |
10. 6.7 CANADA MARKET ANALYSIS BY VECTOR TYPE |
11. 6.8 CANADA MARKET ANALYSIS BY GENE TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY APPLICATION |
13. 6.10 CANADA MARKET ANALYSIS BY DELIVERY METHOD |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY VECTOR TYPE |
16. 6.13 GERMANY MARKET ANALYSIS BY GENE TYPE |
17. 6.14 GERMANY MARKET ANALYSIS BY APPLICATION |
18. 6.15 GERMANY MARKET ANALYSIS BY DELIVERY METHOD |
19. 6.16 UK MARKET ANALYSIS BY VECTOR TYPE |
20. 6.17 UK MARKET ANALYSIS BY GENE TYPE |
21. 6.18 UK MARKET ANALYSIS BY APPLICATION |
22. 6.19 UK MARKET ANALYSIS BY DELIVERY METHOD |
23. 6.20 FRANCE MARKET ANALYSIS BY VECTOR TYPE |
24. 6.21 FRANCE MARKET ANALYSIS BY GENE TYPE |
25. 6.22 FRANCE MARKET ANALYSIS BY APPLICATION |
26. 6.23 FRANCE MARKET ANALYSIS BY DELIVERY METHOD |
27. 6.24 RUSSIA MARKET ANALYSIS BY VECTOR TYPE |
28. 6.25 RUSSIA MARKET ANALYSIS BY GENE TYPE |
29. 6.26 RUSSIA MARKET ANALYSIS BY APPLICATION |
30. 6.27 RUSSIA MARKET ANALYSIS BY DELIVERY METHOD |
31. 6.28 ITALY MARKET ANALYSIS BY VECTOR TYPE |
32. 6.29 ITALY MARKET ANALYSIS BY GENE TYPE |
33. 6.30 ITALY MARKET ANALYSIS BY APPLICATION |
34. 6.31 ITALY MARKET ANALYSIS BY DELIVERY METHOD |
35. 6.32 SPAIN MARKET ANALYSIS BY VECTOR TYPE |
36. 6.33 SPAIN MARKET ANALYSIS BY GENE TYPE |
37. 6.34 SPAIN MARKET ANALYSIS BY APPLICATION |
38. 6.35 SPAIN MARKET ANALYSIS BY DELIVERY METHOD |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY VECTOR TYPE |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY GENE TYPE |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY DELIVERY METHOD |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY VECTOR TYPE |
45. 6.42 CHINA MARKET ANALYSIS BY GENE TYPE |
46. 6.43 CHINA MARKET ANALYSIS BY APPLICATION |
47. 6.44 CHINA MARKET ANALYSIS BY DELIVERY METHOD |
48. 6.45 INDIA MARKET ANALYSIS BY VECTOR TYPE |
49. 6.46 INDIA MARKET ANALYSIS BY GENE TYPE |
50. 6.47 INDIA MARKET ANALYSIS BY APPLICATION |
51. 6.48 INDIA MARKET ANALYSIS BY DELIVERY METHOD |
52. 6.49 JAPAN MARKET ANALYSIS BY VECTOR TYPE |
53. 6.50 JAPAN MARKET ANALYSIS BY GENE TYPE |
54. 6.51 JAPAN MARKET ANALYSIS BY APPLICATION |
55. 6.52 JAPAN MARKET ANALYSIS BY DELIVERY METHOD |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY VECTOR TYPE |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY GENE TYPE |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY DELIVERY METHOD |
60. 6.57 MALAYSIA MARKET ANALYSIS BY VECTOR TYPE |
61. 6.58 MALAYSIA MARKET ANALYSIS BY GENE TYPE |
62. 6.59 MALAYSIA MARKET ANALYSIS BY APPLICATION |
63. 6.60 MALAYSIA MARKET ANALYSIS BY DELIVERY METHOD |
64. 6.61 THAILAND MARKET ANALYSIS BY VECTOR TYPE |
65. 6.62 THAILAND MARKET ANALYSIS BY GENE TYPE |
66. 6.63 THAILAND MARKET ANALYSIS BY APPLICATION |
67. 6.64 THAILAND MARKET ANALYSIS BY DELIVERY METHOD |
68. 6.65 INDONESIA MARKET ANALYSIS BY VECTOR TYPE |
69. 6.66 INDONESIA MARKET ANALYSIS BY GENE TYPE |
70. 6.67 INDONESIA MARKET ANALYSIS BY APPLICATION |
71. 6.68 INDONESIA MARKET ANALYSIS BY DELIVERY METHOD |
72. 6.69 REST OF APAC MARKET ANALYSIS BY VECTOR TYPE |
73. 6.70 REST OF APAC MARKET ANALYSIS BY GENE TYPE |
74. 6.71 REST OF APAC MARKET ANALYSIS BY APPLICATION |
75. 6.72 REST OF APAC MARKET ANALYSIS BY DELIVERY METHOD |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY VECTOR TYPE |
78. 6.75 BRAZIL MARKET ANALYSIS BY GENE TYPE |
79. 6.76 BRAZIL MARKET ANALYSIS BY APPLICATION |
80. 6.77 BRAZIL MARKET ANALYSIS BY DELIVERY METHOD |
81. 6.78 MEXICO MARKET ANALYSIS BY VECTOR TYPE |
82. 6.79 MEXICO MARKET ANALYSIS BY GENE TYPE |
83. 6.80 MEXICO MARKET ANALYSIS BY APPLICATION |
84. 6.81 MEXICO MARKET ANALYSIS BY DELIVERY METHOD |
85. 6.82 ARGENTINA MARKET ANALYSIS BY VECTOR TYPE |
86. 6.83 ARGENTINA MARKET ANALYSIS BY GENE TYPE |
87. 6.84 ARGENTINA MARKET ANALYSIS BY APPLICATION |
88. 6.85 ARGENTINA MARKET ANALYSIS BY DELIVERY METHOD |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY VECTOR TYPE |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY GENE TYPE |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DELIVERY METHOD |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY VECTOR TYPE |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY GENE TYPE |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY DELIVERY METHOD |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY VECTOR TYPE |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY GENE TYPE |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY DELIVERY METHOD |
102. 6.99 REST OF MEA MARKET ANALYSIS BY VECTOR TYPE |
103. 6.100 REST OF MEA MARKET ANALYSIS BY GENE TYPE |
104. 6.101 REST OF MEA MARKET ANALYSIS BY APPLICATION |
105. 6.102 REST OF MEA MARKET ANALYSIS BY DELIVERY METHOD |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY VECTOR TYPE, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY VECTOR TYPE, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY GENE TYPE, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY GENE TYPE, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY DELIVERY METHOD, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY DELIVERY METHOD, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY VECTOR TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY GENE TYPE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Gene Therapy Market Segmentation

Gene Therapy Market By Vector Type (USD Billion, 2025-2035)

Viral Vector
Non-Viral Vector

Gene Therapy Market By Gene Type (USD Billion, 2025-2035)

Antigen
Cytokine
Tumor Suppressor
Suicide
Deficiency
Growth Factors
Receptors
Others

Gene Therapy Market By Application (USD Billion, 2025-2035)

Oncological Disorders
Rare Diseases
Cardiovascular Diseases
Neurological Disorders
Infectious Diseases
Others

Gene Therapy Market By Delivery Method (USD Billion, 2025-2035)

In Vivo Gene Therapy
Ex Vivo Gene Therapy

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”